je.st
news
Tag: patients
New Findings Show Anti-Tumor Activity of KEYTRUDA (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
2015-09-26 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients Results from KEYNOTE-028 Presented at 2015 European Cancer Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) a type of head and neck cancer whose tumors express PD-L1 (1% of cells in tumor nests or PD-L1+ bands in stroma). Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558An Phan, (908) 255-6325orInvestor:Justin Holko, (908) 740-1879Teri Loxam, (908) 740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: show
advanced
activity
patients
Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
2015-09-17 14:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Presents Pivotal Data for Omarigliptin, Mercks Investigational Once-Weekly DPP-4 Inhibitor, and Additional Data from the TECOS CV Safety Trial, at European Association for the Study of Diabetes Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, provided an update today on its diabetes portfolio and re-affirmed the companys comprehensive, long-term commitment to patients with diabetes. Merck has a proud history in helping patients with type 2 diabetes. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (310) 617-1067orInvestor:Justin Holko, +1 (908) 740-1879Teri Loxam, +1 (908) 740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
update
comprehensive
patients
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
New Cohorts From CheckMate -012 Assess Optimal Dosing Of Opdivo+Yervoy In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer
2015-09-08 07:25:25| drugdiscoveryonline Home Page
Bristol-Myers Squibb Company recently announced updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC)
Tags: with
advanced
cell
treatment
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
2015-09-02 07:45:41| drugdiscoveryonline News Articles
Highland Therapeutics Inc. (“Highland”) announced recently that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has dosed the first patient in the second of two pivotal studies of HLD-200
Tags: trial
patients
adhd
announces
Sites : [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] next »